In this GEN webinar, Guilherme Yamamoto, MD, PhD, and Sevana Yaghoubian will present a novel whole-exome assay for detecting high-confidence variants across multiple applications.

Detailed price information for Genedx Holdings Corp (WGS-Q) from The Globe and Mail including charting and trades.

Labcorp , a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians ...

GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that ...

GeneDx reported full-year 2025 revenue of approximately $427M, inline with consensus of $427M, representing a 41% year-over-year increase and within its previously raised guidance range of $425 ...

Genedx Holding Corp. launched Genomedx Prenatal, its whole genome sequencing test, to provide more definitive diagnoses of the causes of fetal abnormalities identified by ultrasound. By combining the ...

GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal ...

The Global Reproductive Genetics Market is estimated to be valued at USD 7.31 Bn in 2025 and is expected to reach USD 16.67 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from ...

A dad found out he has been living with a rare incurable disease for 35 years when he put his son through genetic testing — after dismissing his aches and pains for aging. Robin Schultz, 35, and his ...

Christine Eng, MD, discusses how earlier genome testing, multi-omic tools, rapid sequencing, and improved access can shorten diagnostic timelines and guide care. Christine Eng, MD, Professor of ...

Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GAITHERSBURG, Md.--(BUSINESS ...